Abstract
Tumour lysis syndrome (TLS) in plasma cell dyscrasias is extremely rare. TLS has been described in eight cases of multiple myeloma undergoing high- dose therapy with autologous stem cell transplant (ASCT). Recently, clinical trials of intensive chemotherapy followed by autologous or allogeneic stem cell support has been shown to offer potential benefit in AL (amyloid light- chain) amyloidosis. TLS in primary AL amyloidosis in this setting has not been previously reported. We report a case of TLS in a patient with AL amyloidosis which developed after high-dose melphalan chemotherapy supported by ASCT.
| Original language | English |
|---|---|
| Pages (from-to) | 386-387 |
| Number of pages | 2 |
| Journal | British Journal of Haematology |
| Volume | 107 |
| Issue number | 2 |
| DOIs | |
| State | Published - 1999 |
ASJC Scopus subject areas
- Hematology
Keywords
- ASCT
- Amyloidosis
- Melphalan
- Multiple myeloma
- Tumour lysis syndrome
Fingerprint
Dive into the research topics of 'Acute tumour lysis syndrome: A case in AL amyloidosis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver